Oral immune therapy: targeting the systemic immune system via the gut immune system for the treatment of inflammatory bowel disease

Clinical and Translational Immunology

Volumn 5, Issue 1, 2016, Pages

  Ilan, Yaron ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALEQUEL; AMINO ACID; ANTIGEN; CD3 ANTIBODY; GLYCOSPHINGOLIPID; LIPOPOLYSACCHARIDE ANTIBODY; MERCAPTOPURINE; MONOCLONAL ANTIBODY CD3; NANOBODY; NUTRACEUTICAL; OTELIXIZUMAB; POLYPHENOL; POLYUNSATURATED FATTY ACID; PREBIOTIC AGENT; PROBIOTIC AGENT; PRX 106; TEPLIZUMAB; UNCLASSIFIED DRUG; VISILIZUMAB;

ADAPTIVE IMMUNITY; AUTOIMMUNE DISEASE; COLITIS; CROHN DISEASE; DRUG EFFECT; FUNCTIONAL FOOD; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; INFLAMMATORY BOWEL DISEASE; INNATE IMMUNITY; INTESTINE; INTESTINE FLORA; LACTOCOCCUS LACTIS; LIVER; NONHUMAN; ORAL IMMUNOTHERAPY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 85012145409     PISSN: None     EISSN: 20500068     Source Type: Journal    
DOI: 10.1038/cti.2015.47     Document Type: Review

References (131)

1. Wallace KL, Zheng LB, Kanazawa Y, Shih DQ. Immunopathology of inflammatory bowel disease. World J Gastroenterol 2014; 20: 6–21.
2. Lefrancois L, Puddington L. Intestinal and pulmonary mucosal T cells: local heroes fight to maintain the status quo. Annu Rev Immunol 2006; 24: 681–704.
3. van der Heijden PJ, Stok W, Bianchi AT. Contribution of immunoglobulin-secreting cells in the murine small intestine to the total 'background' immunoglobulin production. Immunology 1987; 62: 551–555.
4. Guy-Grand D, Azogui O, Celli S, Darche S, Nussenzweig MC, Kourilsky P et al. Extrathymic T cell lymphopoiesis: ontogeny and contribution to gut intraepithelial lymphocytes in athymic and euthymic mice. J Exp Med 2003; 197: 333–341.
5. Wang X, Sherman A, Liao G, Leong KW, Daniell H, Terhorst C et al. Mechanism of oral tolerance induction to therapeutic proteins. Adv Drug Deliv Rev 2013; 65: 759–773.
6. Castro-Sanchez P, Martin-Villa JM. Gut immune system and oral tolerance. Br J Nutr 2013; 109 (Suppl 2): S3–11.
7. Faria AM, Weiner HL. Oral tolerance. Immunol Rev 2005; 206: 232–259.
8. Pabst O, Herbrand H, Friedrichsen M, Velaga S, Dorsch M, Berhardt G et al. Adaptation of solitary intestinal lymphoid tissue in response to microbiota and chemokine receptor CCR7 signaling. J Immunol 2006; 177: 6824–6832.
9. Pabst R, Rothkotter HJ. Structure and function of the gut mucosal immune system. Adv Exp Med Biol 2006; 579: 1–14.
10. Faria AM, Weiner HL. Oral tolerance: therapeutic implications for autoimmune diseases. Clin Dev Immunol 2006; 13: 143–157.
11. Mizrahi M, Ilan Y. The gut mucosa as a site for induction of regulatory T-cells. Curr Pharm Des 2009; 15: 1191–1202.
12. Ilan Y. Oral tolerance: can we make it work? Hum Immunol 2009; 70: 768–776.
13. Shlomai A, Trop S, Gotsman I, Jurim O, Diment J, Alper R et al. Immunomodulation of experimental colitis: the role of NK1.1 liver lymphocytes and surrogate antigens—bystander effect. J Pathol 2001; 195: 498–507.
14. Brandtzaeg P, Pabst R. Let's go mucosal: communication on slippery ground. Trends Immunol 2004; 25: 570–577.
15. Ilan Y, Maron R, Tukpah AM, Maioli TU, Murugaiyan G, Yang K et al. Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob/ob mice. Proc Natl Acad Sci USA 2010; 107: 9765–9770.
16. Nguyen DL, Flores S, Sassi K, Bechtold ML, Nguyen ET, Parekh NK. Optimizing the use of anti-tumor necrosis factor in the management of patients with Crohn's disease. Ther Adv Chronic Dis 2015; 6: 147–154.
17. Goel RM, Blaker P, Mentzer A, Fong SC, Marinaki AM, Sanderson JD. Optimizing the use of thiopurines in inflammatory bowel disease. Ther Adv Chronic Dis 2015; 6: 138–146.
18. Moss AC. Optimizing the use of biological therapy in patients with inflammatory bowel disease. Gastroenterol Rep 2015; 3: 63–68.
19. Mann ER, Landy JD, Bernardo D, Peake ST, Hart AL, Al-Hassi HO et al. Intestinal dendritic cells: their role in intestinal inflammation, manipulation by the gut microbiota and differences between mice and men. Immunol Lett 2013; 150: 30–40.
20. + T Cells in the Intestine. Front Immunol 2014; 5: 488.
21. Kurashima Y, Goto Y, Kiyono H. Mucosal innate immune cells regulate both gut homeostasis and intestinal inflammation. Eur J Immunol 2013; 43: 3108–3115.
22. Magrone T, Jirillo E. The interplay between the gut immune system and microbiota in health and disease: nutraceutical intervention for restoring intestinal homeostasis. Curr Pharm Des 2013; 19: 1329–1342.
23. Foersch S, Waldner MJ, Neurath MF. Innate and adaptive immunity in inflammatory bowel diseases. Dig Dis 2013; 31: 317–320.
24. Rescigno M. Dendritic cell-epithelial cell crosstalk in the gut. Immunol Rev 2014; 260: 118–128.
25. Wittkopf N, Neurath MF, Becker C. Immune-epithelial crosstalk at the intestinal surface. J Gastroenterol 2014; 49: 375–387.
26. Randall-Demllo S, Chieppa M, Eri R. Intestinal epithelium and autophagy: partners in gut homeostasis. Front Immunol 2013; 4: 301.
27. Merga Y, Campbell BJ, Rhodes JM. Mucosal barrier, bacteria and inflammatory bowel disease: possibilities for therapy. Dig Dis 2014; 32: 475–483.
28. Pelaseyed T, Bergstrom JH, Gustafsson JK, Ermund A, Birchenough GM, Schutte A et al. The mucus and mucins of the goblet cells and enterocytes provide the first defense line of the gastrointestinal tract and interact with the immune system. Immunol Rev 2014; 260: 8–20.
29. Ghishan FK, Kiela PR. Epithelial transport in inflammatory bowel diseases. Inflamm Bowel Dis 2014; 20: 1099–1109.
30. Lee SH. Intestinal permeability regulation by tight junction: implication on inflammatory bowel diseases. Intest Res 2015; 13: 11–18.
31. Cader MZ, Kaser A. Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation. Gut 2013; 62: 1653–1664.
32. Dupaul-Chicoine J, Dagenais M, Saleh M. Crosstalk between the intestinal microbiota and the innate immune system in intestinal homeostasis and inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 2227–2237.
33. Siggers RH, Hackam DJ. The role of innate immune-stimulated epithelial apoptosis during gastrointestinal inflammatory diseases. Cell Mol Life Sci 2011; 68: 3623–3634.
34. Rescigno M, Di Sabatino A. Dendritic cells in intestinal homeostasis and disease. J Clin Invest 2009; 119: 2441–2450.
35. Ng SC, Kamm MA, Stagg AJ, Knight SC. Intestinal dendritic cells: their role in bacterial recognition, lymphocyte homing, and intestinal inflammation. Inflamm Bowel Dis 2010; 16: 1787–1807.
36. Magnusson MK, Wick MJ. Intestinal dendritic cell and macrophage subsets: tipping the balance to Crohn's disease? Eur J Microbiol Immunol 2011; 1: 19–24.
37. Rutella S, Locatelli F. Intestinal dendritic cells in the pathogenesis of inflammatory bowel disease. World J Gastroenterol 2011; 17: 3761–3775.
38. Monteiro M, Graca L. iNKT cells: innate lymphocytes with a diverse response. Crit Rev Immunol 2014; 34: 81–90.
39. Middendorp S, Nieuwenhuis EE. NKT cells in mucosal immunity. Mucosal Immunol 2009; 2: 393–402.
40. Zeissig S, Blumberg RS. Commensal microbial regulation of natural killer T cells at the frontiers of the mucosal immune system. FEBS Lett 2014; 588: 4188–4194.
41. Zeissig S, Blumberg RS. Commensal microbiota and NKT cells in the control of inflammatory diseases at mucosal surfaces. Curr Opin Immunol 2013; 25: 690–696.
42. Liao CM, Zimmer MI, Wang CR. The functions of type I and type II natural killer T cells in inflammatory bowel diseases. Inflamm Bowel Dis 2013; 19: 1330–1338.
43. Trop S, Samsonov D, Gotsman I, Alper R, Diment J, Ilan Y. Liver-associated lymphocytes expressing NK1.1 are essential for oral immune tolerance induction in a murine model. Hepatology 1999; 29: 746–755.
44. Zigmond E, Preston S, Pappo O, Lalazar G, Margalit M, Shalev Z et al. Beta-glucosylceramide: a novel method for enhancement of natural killer T lymphoycte plasticity in murine models of immune-mediated disorders. Gut 2007; 56: 82–89.
45. Ilan Y, Weksler-Zangen S, Ben-Horin S, Diment J, Sauter B, Rabbani E et al. Treatment of experimental colitis by oral tolerance induction: a central role for suppressor lymphocytes. Am J Gastroenterol 2000; 95: 966–973.
46. Gotsman I, Shlomai A, Alper R, Rabbani E, Engelhardt D, Ilan Y. Amelioration of immune-mediated experimental colitis: tolerance induction in the presence of preexisting immunity and surrogate antigen bystander effect. J Pharmacol Exp Ther 2001; 297: 926–932.
47. Israeli E, Safadi R, Melhem A, Pappo O, Shibolet O, Klein A et al. Induction of oral immune regulation towards liver-extracted proteins for treatment of chronic HBV and HCV hepatitis: results of a phase I clinical trial. Liver Int 2004; 24: 295–307.
48. Kim YJ, Chang SY, Ko HJ. Myeloid-derived suppressor cells in inflammatory bowel disease. Intest Res 2015; 13: 105–111.
49. Shalev I, Schmelzle M, Robson SC, Levy G. Making sense of regulatory T cell suppressive function. Semin Immunol 2011; 23: 282–292.
50. Pesenacker AM, Broady R, Levings MK. Control of tissue-localized immune responses by human regulatory T cells. Eur J Immunol 2015; 45: 333–343.
51. Gibson DJ, Ryan EJ, Doherty GA. Keeping the bowel regular: the emerging role of Treg as a therapeutic target in inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 2716–2724.
52. Pabst O. Trafficking of regulatory T cells in the intestinal immune system. Int Immunol 2013; 25: 139–143.
53. Izcue A, Coombes JL, Powrie F. Regulatory lymphocytes and intestinal inflammation. Annu Rev Immunol 2009; 27: 313–338.
54. Bollrath J, Powrie FM. Controlling the frontier: regulatory T-cells and intestinal homeostasis. Semin Immunol 2013; 25: 352–357.
55. Feng T, Elson CO. Adaptive immunity in the host-microbiota dialog. Mucosal Immunol 2011; 4: 15–21.
56. Hardenberg G, Steiner TS, Levings MK. Environmental influences on T regulatory cells in inflammatory bowel disease. Semin Immunol 2011; 23: 130–138.
57. Mayne CG, Williams CB. Induced and natural regulatory T cells in the development of inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 1772–1788.
58. Ai TL, Solomon BD, Hsieh CS. T-cell selection and intestinal homeostasis. Immunol Rev 2014; 259: 60–74.
59. Xu XR, Liu CQ, Feng BS, Liu ZJ. Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease. World J Gastroenterol 2014; 20: 3255–3264.
60. Galvez J. Role of Th17 Cells in the Pathogenesis of Human IBD. ISRN Inflamm 2014 2014, 928461.
61. Cerovic V, Bain CC, Mowat AM, Milling SW. Intestinal macrophages and dendritic cells: what's the difference? Trends Immunol 2014; 35: 270–277.
62. Bain CC, Mowat AM. The monocyte-macrophage axis in the intestine. Cell Immunol 2014; 291: 41–48.
63. Bain CC, Mowat AM. Macrophages in intestinal homeostasis and inflammation. Immunol Rev 2014; 260: 102–117.
64. Lopetuso LR, Scaldaferri F, Petito V, Gasbarrini A. Commensal Clostridia: leading players in the maintenance of gut homeostasis. Gut Pathog 2013; 5: 23.
65. Kuhn KA, Stappenbeck TS. Peripheral education of the immune system by the colonic microbiota. Semin Immunol 2013; 25: 364–369.
66. Kamada N, Nunez G. Regulation of the immune system by the resident intestinal bacteria. Gastroenterology 2014; 146: 1477–1488.
67. Almeida J, Galhenage S, Yu J, Kurtovic J, Riordan SM. Gut flora and bacterial translocation in chronic liver disease. World J Gastroenterol 2006; 12: 1493–1502.
68. Szabo G, Bala S, Petrasek J, Gattu A. Gut-liver axis and sensing microbes. Dig Dis 2010; 28: 737–744.
69. Koboziev I, Reinoso Webb C, Furr KL, Grisham MB. Role of the enteric microbiota in intestinal homeostasis and inflammation. Free Rad Biol Med 2014; 68: 122–133.
70. Odenwald MA, Turner JR. Intestinal permeability defects: is it time to treat? Clin Gastroenterol Hepatol 2013; 11: 1075–1083.
71. Dalal SR, Chang EB. The microbial basis of inflammatory bowel diseases. J Clin Invest 2014; 124: 4190–4196.
72. Klapproth JM, Sasaki M. Bacterial induction of proinflammatory cytokines in inflammatory bowel disease. Inflamm Bowel Dis 2010; 16: 2173–2179.
73. Tawfik A, Flanagan PK, Campbell BJ. Escherichia coli-host macrophage interactions in the pathogenesis of inflammatory bowel disease. World J Gastroenterol 2014; 20: 8751–8763.
74. Shapiro JM, Cho JH, Sands BE, LeLeiko NS. Bridging the gap between host immune response and intestinal dysbiosis in inflammatory bowel disease: does immunoglobulin A mark the spot? Clin Gastroenterol Hepatol 2015; 13: 842–846.
75. Strober W. Impact of the gut microbiome on mucosal inflammation. Trends Immunol 2013; 34: 423–430.
76. MacDonald TT, Vossenkaemper A, Fantini M, Monteleone G. Reprogramming the immune system in IBD. Dig Dis 2012; 30: 392–395.
77. Colman RJ, Rubin DT. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis 2014; 8: 1569–1581.
78. Ma HD, Wang YH, Chang C, Gershwin ME, Lian ZX. The intestinal microbiota and microenvironment in liver. Autoimmun Rev 2015; 14: 183–191.
79. Navaneethan U. Hepatobiliary manifestations of ulcerative colitis: an example of gut-liver crosstalk. Gastroenterology report 2014; 2: 193–200.
80. Visschers RG, Luyer MD, Schaap FG, Olde Damink SW, Soeters PB. The gut-liver axis. Curr Opin Clin Nutr Metab Care 2013; 16: 576–581.
81. Chassaing B, Etienne-Mesmin L, Gewirtz AT. Microbiota-liver axis in hepatic disease. Hepatology 2014; 59: 328–339.
82. Seidel D, Eickmeier I, Kuhl AA, Hamann A, Loddenkemper C, Schott E. CD8 T cells primed in the gut-associated lymphoid tissue induce immune-mediated cholangitis in mice. Hepatology 2014; 59: 601–611.
83. Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011; 474: 298–306.
84. Israeli E, Goldin E, Shibolet O, Klein A, Hemed N, Engelhardt D et al. Oral immune regulation using colitis extracted proteins for treatment of Crohn's disease: results of a phase I clinical trial. World J Gastroenterol 2005; 11: 3105–3111.
85. Margalit M, Israeli E, Shibolet O, Zigmond E, Klein A, Hemed N et al. A double-blind clinical trial for treatment of Crohn's disease by oral administration of Alequel, a mixture of autologous colon-extracted proteins: a patient-tailored approach. Am J Gastroenterol 2006; 101: 561–568.
86. Israeli E, Zigmond E, Lalazar G, Klein A, Hemed N, Goldin E et al. Oral mixture of autologous colon-extracted proteins for the Crohn's disease: a double-blind trial. World J Gastroenterol 2015; 21: 5685–5694.
87. Israeli ED, Ilan A, Y, Long-term Y. Efect of short-term oral administration of a mixture of autologous proteins extracted from the colon of patients with Crohn's disease: a memory effect of oral tolerance induction. J Gastroenterol Hepatol 2015; 2: 12.
88. Waters OR, Lawrance IC. Understanding the use of immunosuppressive agents in the clinical management of IBD. Curr Drug Targets 2011; 12: 1364–1371.
89. Gilissen LP, Wong DR, Engels LG, Bierau J, Bakker JA, Paulussen AD et al. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy. J Crohns Colitis 2012; 6: 698–707.
90. Hanauer SB, Korelitz BI, Rutgeerts P, Peppercorn MA, Thisted RA, Cohen RD et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004; 127: 723–729.
91. Mate-Jimenez J, Hermida C, Cantero-Perona J, Moreno-Otero R. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000; 12: 1227–1233.
92. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119: 895–902.
93. Amin J, Huang B, Yoon J, Shih DQ. Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD. Inflamm Bowel Dis 2015; 21: 445–452.
94. Israeli E, Goldin E, Fishman S, Konikoff F, Lavy A, Chowers Y et al. Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trial. Clin Exp Immunol 2015; 181: 362–372.
95. Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol 2003; 3: 123–132.
96. Chatenoud L, Waldmann H. CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic. Rev Diabet Stud 2012; 9: 372–381.
97. Yu QT, Saruta M, Papadakis KA. Visilizumab induces apoptosis of mucosal T lymphocytes in ulcerative colitis through activation of caspase 3 and 8 dependent pathways. Clin Immunol 2008; 127: 322–329.
98. Vossenkamper A, Hundsrucker C, Page K, van Maurik A, Sanders TJ, Stagg AJ et al. A CD3-specific antibody reduces cytokine production and alters phosphoprotein profiles in intestinal tissues from patients with inflammatory bowel disease. Gastroenterology 2014; 147: 172–183.
99. Dean Y, Depis F, Kosco-Vilbois M. Combination therapies in the context of anti-CD3 antibodies for the treatment of autoimmune diseases. Swiss Med Wkly 2012; 142: w13711.
100. Weiner HL, da Cunha AP, Quintana F, Wu H. Oral tolerance. Immunol Rev 2011; 241: 241–259.
101. Ochi H, Abraham M, Ishikawa H, Frenkel D, Yang K, Basso A et al. New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity. J Neurol Sci 2008; 274: 9–12.
102. + T cells. Nat Med 2006; 12: 627–635.
103. Ishikawa H, Ochi H, Chen ML, Frenkel D, Maron R, Weiner HL. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody. Diabetes 2007; 56: 2103–2109.
104. Wu HY, Center EM, Tsokos GC, Weiner HL. Suppression of murine SLE by oral anti-CD3: inducible CD4+CD25-LAP+ regulatory T cells control the expansion of IL-17+ follicular helper T cells. Lupus 2009; 18: 586–596.
105. Wu HY, Quintana FJ, Weiner HL. Nasal anti-CD3 antibody ameliorates lupus by inducing an IL-10-secreting CD4+ CD25- LAP+ regulatory T cell and is associated with down-regulation of IL-17+ CD4+ ICOS+ CXCR5+ follicular helper T cells. J Immunol 2008; 181: 6038–6050.
106. Forster K, Goethel A, Chan CW, Zanello G, Streutker C, Croitoru K. An oral CD3-specific antibody suppresses T-cell-induced colitis and alters cytokine responses to T-cell activation in mice. Gastroenterology 2012; 143: 1298–1307.
107. Ilan Y, Zigmond E, Lalazar G, Dembinsky A, Ben Ya'acov A, Hemed N et al. Oral administration of OKT3 monoclonal antibody to human subjects induces a dose-dependent immunologic effect in T cells and dendritic cells. J Clin Immunol 2010; 30: 167–177.
108. Lalazar G, Mizrahi M, Turgeman I, Adar T, Ben Ya'acov A, Shabat Y et al. Oral administration of OKT3 MAb to patients with NASH, promotes regulatory T-cell induction, and alleviates insulin resistance: results of a phase IIa blinded placebo-controlled trial. J Clin Immunol 2015; 35: 399–407.
109. Adar T, Ben Ya'acov A, Lalazar G, Lichtenstein Y, Nahman D, Mizrahi M et al. Oral administration of immunoglobulin G-enhanced colostrum alleviates insulin resistance and liver injury and is associated with alterations in natural killer T cells. Clin Exp Immunol 2012; 167: 252–260.
110. Mizrahi MLG, Shabat Y, Adar T, Ben Ya'acov A, Ilan Y. Alleviation of insulin resistance and liver damage by oral administration of etec colostrums is mediated by increased GLP-1, adiponectin serum levels and tregs: results of a phase I/II clinical trial in NASH. Hepatology 2010; 52: 163A.
111. Ya'acov AB, Lichtenstein Y, Zolotarov L, Ilan Y. The gut microbiome as a target for regulatory T cells-based immunotherapy: induction of regulatory lymphocytes by oral administration of anti-LPS enriched colostrum alleviates immune mediated colitis. BMC Gastroenterol 2015; 15: 154.
112. Ilan Y, Elstein D, Zimran A. Glucocerebroside: an evolutionary advantage for patients with Gaucher disease and a new immunomodulatory agent. Immunol Cell Biol 2009; 87: 514–524.
113. Radin NS, Inokuchi J. Glucosphingolipids as sites of action in the chemotherapy of cancer. Biochem Pharmacol 1988; 37: 2879–2886.
114. Margalit M, Ghazala SA, Alper R, Elinav E, Klein A, Doviner V et al. Glucocerebroside treatment ameliorates ConA hepatitis by inhibition of NKT lymphocytes. Am J Physiol Gastrointest Liver Physiol 2005; 289: G917–G925.
115. Margalit M, Shalev Z, Pappo O, Sklair-Levy M, Alper R, Gomori M et al. Glucocerebroside ameliorates the metabolic syndrome in OB/OB mice. J Pharmacol Exp Ther 2006; 319: 105–110.
116. Zigmond E, Tayer-Shifman O, Lalazar G, Ben Ya'acov A, Weksler-Zangen S, Shasha D et al. beta-glycosphingolipids ameliorated non-alcoholic steatohepatitis in the Psammomys obesus model. J Inflamm Res 2014; 7: 151–158.
117. Zigmond E, Zangen SW, Pappo O, Sklair-Levy M, Lalazar G, Zolotaryova L et al. Beta-glycosphingolipids improve glucose intolerance and hepatic steatosis of the Cohen diabetic rat. Am J Physiol Endocrinol Metab 2009; 296: E72–E78.
118. Lalazar GZE, Zangen SW, Pappo O, Levy Sklair M, Hemed N, Raz I et al. Treatment of insulin rsistance and non-alcoholic steatohepatitis by administration of beta glucosylceramide controlled trial. Hepatology 2009; 50: 200A (Suppl 204).
119. Scott LJ. Etanercept: a review of its use in autoimmune inflammatory diseases. Drugs 2014; 74: 1379–1410.
120. Olivieri I, D'Angelo S, Palazzi C, Padula A. Advances in the management of psoriatic arthritis. Nat Rev Rheumatol 2014; 10: 531–542.
121. Armuzzi A, Lionetti P, Blandizzi C, Caporali R, Chimenti S, Cimino L et al. anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab. Int J Immunopathol Pharmacol 2014; 27 (1 Suppl): 11–32.
122. Varkas G, Van Praet L, Cypers H, Elewaut D. Spondyloarthritis and inflammatory bowel disease. Comorbidity and treatment implications. Z Rheumatol 2013; 72: 524–529.
123. Van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003; 124: 1774–1785.
124. Shaaltiel Y, Ya'acov AB, Shabbat Y, Zolotarov L, Gingis-Velitski S, Almon E et al. A novel method for anti-TNF based-oral immunotherapy: oral administration of a plant cell-expressed recombinant anti-TNF fusion protein for treating of Crohn's disease. Gastroenterology 2014; 146: S-901.
125. Rottiers P, De Smedt T, Steidler L. Modulation of gut-associated lymphoid tissue functions with genetically modified Lactococcus lactis. Int Rev Immunol 2009; 28: 465–486.
126. Robert S, Gysemans C, Takiishi T, Korf H, Spagnuolo I, Sebastiani G et al. Oral delivery of glutamic acid decarboxylase (GAD)-65 and IL10 by Lactococcus lactis reverses diabetes in recent-onset NOD mice. Diabetes 2014; 63: 2876–2887.
127. Vandenbroucke K, de Haard H, Beirnaert E, Dreier T, Lauwereys M, Huyck L et al. Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis. Mucosal Immunol 2010; 3: 49–56.
128. Andrade ME, Araujo RS, de Barros PA, Soares AD, Abrantes FA, Generoso SV et al. The role of immunomodulators on intestinal barrier homeostasis in experimental models. Clin Nutr 2015; 34: 1080–1087.
129. Ramakrishna BS. Probiotic-induced changes in the intestinal epithelium: implications in gastrointestinal disease. Trop Gastroenterol 2009; 30: 76–85.
130. Ng SC, Hart AL, Kamm MA, Stagg AJ, Knight SC. Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis 2009; 15: 300–310.
131. Sinagra E, Tomasello G, Cappello F, Leone A, Cottone M, Bellavia M et al. Probiotics, prebiotics and symbiotics in inflammatory bowel diseases: state-of-the-art and new insights. J Biol Regul Homeost Agents 2013; 27: 919–933.